Deutsche Bank reissued their sell rating on shares of ConvaTec Group (LON:CTEC) in a research note released on Thursday.
Several other analysts have also weighed in on CTEC. Credit Suisse Group restated a neutral rating and set a GBX 215 ($3.00) price target on shares of ConvaTec Group in a report on Wednesday, April 25th. Peel Hunt restated a hold rating and set a GBX 210 ($2.93) price target on shares of ConvaTec Group in a report on Wednesday. Numis Securities restated a hold rating and set a GBX 180 ($2.51) price target on shares of ConvaTec Group in a report on Wednesday. Finally, Citigroup restated a neutral rating and set a GBX 226 ($3.15) price target on shares of ConvaTec Group in a report on Friday, February 16th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of GBX 238.27 ($3.32).
LON:CTEC opened at GBX 228.20 ($3.18) on Thursday. ConvaTec Group has a fifty-two week low of GBX 181.40 ($2.53) and a fifty-two week high of GBX 349.10 ($4.87).
The firm also recently announced a dividend, which will be paid on Thursday, May 17th. Shareholders of record on Thursday, April 5th will be paid a $0.04 dividend. The ex-dividend date of this dividend is Thursday, April 5th. This represents a yield of 1.42%.
ConvaTec Group Company Profile
ConvaTec Group Plc is a medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions.
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.